Work

SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.3024

Authors: Antoine Hollebecque, Juanita Suzanne Lopez, Sarina A. Piha-Paul, Afshin Dowlati, Amita Patnaik, Vladimir Galvao, Bruno Bockorny, Kartik Sehgal, Ed Kingsley, Rachel E. Sanborn, Cesar Augusto Perez, Solange Peters, Mingjin Yan, Natalya N. Nazarenko, Emiliano Calvo

Institutions: Institut Gustave Roussy, Royal Marsden Hospital, The University of Texas MD Anderson Cancer Center, University Hospitals Seidman Cancer Center, Case Western Reserve University, South Texas Accelerated Research Therapeutics, Vall d'Hebron Institute of Oncology, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Comprehensive Cancer Centers of Nevada, Providence Portland Medical Center, Centre Hospitalier Universitaire Vaudois, Seagen (United States)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Seagen

OpenAlex ID: W4379282771

Cites:

Cited by: 17

Related to: 10